Cytomed TherapeuticsGDTC
13F holders, Q3 2025 (September 30)2holders
1new positions
1sold out
$1.99avg. 13F price*
At the end of Q3 2025, 2 institutions reported holding Cytomed Therapeutics Ltd. (GDTC) in their 13F filings, unchanged from Q2 2025. 1 opened new positions and 1 sold out. The largest holders were UBS Group AG ($26K) and Wealthspire Advisors, LLC ($10K).
- Company
- Cytomed Therapeutics Ltd.
- CUSIP
- Y1R80M106
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $10K |
| Exits | 1 | $59K |
All 13F filers, Q2 2025 → Q3 2025: 4,835 shares bought and 31,961 shares sold, net −27,126 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| UBS Group AG | 0.00% | Reduce -24.4% | 13,289 | $26K |
| Wealthspire Advisors, LLC | 0.00% | New | 4,835 | $10K |
"% of holder's portfolio" is GDTC's weight in each manager's 13F, not the share of Cytomed Therapeutics Ltd. the manager owns.